Business Context and Reporting Period
Company: SeaStar Medical Holding Corporation (NASDAQ: ICU)
Filing Type: Form 8-K (Current Report)
Date of Report: January 26, 2024
Event: Entry into a Material Definitive Agreement for a registered direct offering and concurrent private placement.
Key Financial Metrics and Transaction Details
Capital Raised: The Company expects to receive aggregate gross proceeds of approximately $9.0 million, before deducting fees and offering expenses.
Securities Issued:
- Common Stock: 6,304,545 shares issued in a registered direct offering.
- Pre-Funded Warrants: 4,536,216 warrants to purchase Common Stock at an exercise price of $0.0001 per share.
- Series A Common Warrants: 10,840,761 warrants to purchase Common Stock at an exercise price of $0.8302 per share.
- Series B Common Warrants: 5,420,381 warrants to purchase Common Stock at an exercise price of $0.8302 per share.
Placement Agent Fees: Maxim Group LLC will receive a cash fee of 7% of aggregate gross proceeds plus reimbursement of out-of-pocket expenses. Additionally, the agent will receive warrants covering 5% of the total shares sold, exercisable at 110% of the offering price.
Debt and Liquidity: The filing does not provide specific current liquidity figures, debt balances, or cash flow metrics. It notes the existence of convertible notes from March 2023.
Material Changes and Debt Considerations
Convertible Note Redemption Rights: In connection with this offering, the holder of the March 2023 convertible notes agreed to waive their Optional Redemption Rights and suspend them for 60 days following the closing. Following this suspension period, the investor has the right to redeem all or a portion of the outstanding Conversion Amount at 200% of the Conversion Amount within three trading days.
Stockholder Approval: The Series A and Series B Common Warrants are exercisable only after stockholder approval for the issuance of the underlying shares. The Series A warrants expire five years after the approval date, while Series B warrants expire 12 months after the approval date.
Guidance, Outlook, and Risks
Management Commentary: The filing focuses on the execution of the capital raise and does not provide specific operational guidance, revenue forecasts, or margin outlooks.
Risks and Contingencies:
- Dilution: The issuance of significant numbers of shares and warrants will result in dilution to existing shareholders.
- Debt Redemption Risk: The potential redemption of convertible notes at 200% of the conversion amount post-suspension period represents a significant contingent liability.
- Regulatory Approval: The exercisability of the Common Warrants is contingent upon stockholder approval.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received after deducting the 7% placement fee and other expenses.
- Confirm the timeline for the stockholder vote required to make the Series A and Series B warrants exercisable.
- Review the outstanding balance of the March 2023 convertible notes to assess the potential cash outflow if the 200% redemption option is exercised after the 60-day suspension period.
- Monitor the Company's cash burn rate to determine how long the $9.0 million in gross proceeds will sustain operations.
- Check for any subsequent filings regarding the effectiveness of the registration statement for the resale of Common Warrant Shares.